Navigation Links
Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
Date:1/27/2011

in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2009, our Form 10-Q for the nine months ended September 30, 2010, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured,
'/>"/>
SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... FRANKLIN, Ohio , Jan. 15, 2014  A novel wearable ... it easy and painless for patients to self-inject prescription drugs ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic ... expected to grow to $220B by 2018, according to analysts.   ...
(Date:1/14/2014)... , Jan. 14, 2014 Dynamic Healthcare Services, Inc. ... today that it acquired Progressive Home Medical Equipment, Inc. ("Progressive") ... 2014. The terms of the acquisition were not disclosed. ... ("DME") company providing a wide range of sleep, mobility, and ...
(Date:1/14/2014)... Inc. , a privately held company pioneering the development ... related neurodegenerative disorders, announced today the relocation of its ... as of January 15, 2014 and expanded lease agreement ... Oligomerix, which is focused on the development ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... New Jersey, October 7, 2010 ... ... ... keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
... ZMH and SIX: ZMH) announced today its ... broadcast live over the Internet on Thursday, Oct. 28, 2010, ... quarterly results will be made available at 7:00 a.m. Eastern ... The live audio webcast can be accessed via Zimmer,s Investor ...
Cached Medicine Technology:International Medical News Group Relaunches Internal Medicine News Digital Network and Hospitalist News Digital Network 2International Medical News Group Relaunches Internal Medicine News Digital Network and Hospitalist News Digital Network 3International Medical News Group Relaunches Internal Medicine News Digital Network and Hospitalist News Digital Network 4International Medical News Group Relaunches Internal Medicine News Digital Network and Hospitalist News Digital Network 5International Medical News Group Relaunches Internal Medicine News Digital Network and Hospitalist News Digital Network 6International Medical News Group Relaunches Internal Medicine News Digital Network and Hospitalist News Digital Network 7International Medical News Group Relaunches Internal Medicine News Digital Network and Hospitalist News Digital Network 8Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2010 Results 2
(Date:4/18/2014)... being prepped to enter the battle against infectious ... diseases in remote areas, thanks in part to ... the International Space Station on the behavior of ... capillary flow to diagnose infectious diseases such as ... researcher at Northwestern University in Evanston, Ill., had ...
(Date:4/18/2014)... researchers have been awarded two-year grants for their work ... month. Of the 110 initial submissions to the new ... only four projects were funded, three of which are ... M.D., Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, ... oncology, will use his $500,000 proof of principle grant ...
(Date:4/18/2014)... Two Simon Fraser University psychologists have made a ... treatment of attention-deficit disorders. , This discovery opens ... may hinder or suppress a specific brain activity ... prevent distraction. , The Journal of Neuroscience ... discovery by John McDonald, an associate professor of ...
(Date:4/18/2014)... lead to potential new treatments for breaking the cycle ... Fibrosis, or scarring, is a hallmark of the disease, ... lead to serious organ damage and, in some cases, ... on findings made by Swati Bhattacharyya, PhD, research assistant ... specific protein plays in promoting fibrosis. , "Our ...
(Date:4/17/2014)... variant specifically associated with the risk of a ... cent of all breast cancer cases. , The ... called invasive lobular carcinoma, gives researchers important clues ... of breast cancer, which can be missed through ... the journal PloS Genetics , was co-led ...
Breaking Medicine News(10 mins):Health News:Space-tested fluid flow concept advances infectious disease diagnoses 2Health News:Space-tested fluid flow concept advances infectious disease diagnoses 3Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3
... MDTH ) announced that its senior management will give ... January,7 - 10, 2008 at the Westin St. Francis ... give its presentation on Thursday,January 10, 2008 at 10:00 ... the Internet via MedCath,s website (http://www.medcath.com ) and,will ...
... Show with, Fashions by Chloe Dao, Presented by Rachel Hunter, Benefiting Dress ... ... Culminating a year of,empowering women to ,find their slim, and supporting the ... with the Style Your Slim(SM) Fashion Show in Los Angeles, CA, on,January 8th. ...
... SOUTH WINDSOR, Conn., Jan. 2 Gerber,Scientific, Inc. (NYSE: ... announced that Marc T. Giles, President and Chief Executive,Officer, ... Conference,being held in New York on Tuesday, January 8, ... of the presentation will be available on the home ...
... of Aetna, Inc., LOVELAND, Colo., Jan. 2 ... that Ms. Louise McCormick has joined the,company,s Board ... "We pride ourselves on our commitment to excellence ... quality, independent Directors,is critical to this effort," said ...
... finds whites are prescribed opioids more often than blacks, Hispanics ... in an emergency room in significant pain, you are less ... if you are not white, new research shows. , The ... that minorities don,t get effective pain treatment in the ER ...
... benefits outweigh its risks , , WEDNESDAY, Jan. 2 (HealthDay ... cause high blood pressure in patients with kidney cancer, ... of a study published last month that found the ... failure among patients with stomach cancer. , "Patients taking ...
Cached Medicine News:Health News:Slim-Fast Celebrates Weight Loss by Hosting Style Your Slim(SM) Fashion Show Featuring Real Women 2Health News:Slim-Fast Celebrates Weight Loss by Hosting Style Your Slim(SM) Fashion Show Featuring Real Women 3Health News:Slim-Fast Celebrates Weight Loss by Hosting Style Your Slim(SM) Fashion Show Featuring Real Women 4Health News:Gerber Scientific to Present at 10th Annual Needham Growth Stock Conference 2Health News:Louise McCormick Joins Heska's Board of Directors 2Health News:Louise McCormick Joins Heska's Board of Directors 3Health News:Minorities Less Likely to Get Powerful Painkillers in ER 2Health News:Minorities Less Likely to Get Powerful Painkillers in ER 3Health News:New Cancer Drug Boosts Blood Pressure 2Health News:New Cancer Drug Boosts Blood Pressure 3
Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol...
Ready to use liquid single reagent for automated chemistry analyzers. Linearity to 1000 mmol/L...
The new ProteomeX Workstation enables the rapid set up, execution and analysis of multidimensional LC/MS methods, providing you with the best possible technique to characterize your complex proteomic...
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 1000 mg/dL (11.3 mmol/L). Single vial, dry powder reagent....
Medicine Products: